How to Differentiate Benign from Malignant Adrenocortical Tumors?
暂无分享,去创建一个
L. Hofland | R. Feelders | S. Creemers | F. V. van Kemenade | T. V. van Ginhoven | C. Viëtor | Tessa M. van Ginhoven
[1] A. Lam. Adrenocortical Carcinoma: Updates of Clinical and Pathological Features after Renewed World Health Organisation Classification and Pathology Staging , 2021, Biomedicines.
[2] E. Caoili,et al. 18F-FDG-PET/CT Evaluation of Indeterminate Adrenal Masses in Non-Cancer Patients. , 2021, The Journal of clinical endocrinology and metabolism.
[3] M. Mannelli,et al. Prognostic and Monitoring Value of Circulating Tumor Cells in Adrenocortical Carcinoma: A Preliminary Monocentric Study , 2020, Cancers.
[4] Bangshun He,et al. The diagnostic and prognostic values of microRNA-196a in cancer , 2020, Bioscience reports.
[5] R. Aneja,et al. Adrenal gland fine needle aspiration: a multi-institutional analysis of 139 cases. , 2020, Journal of the American Society of Cytopathology.
[6] Han-Zhong Li,et al. Sum of High-Risk Gene Mutation (SHGM): A Novel Attempt to Assist Differential Diagnosis for Adrenocortical Carcinoma with Benign Adenoma, Based on Detection of Mutations of Nine Target Genes , 2020, Biochemical Genetics.
[7] G. Hutvagner,et al. Key MicroRNA’s and Their Targetome in Adrenocortical Cancer , 2020, Cancers.
[8] Michael Biehl,et al. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study , 2020, The lancet. Diabetes & endocrinology.
[9] B. Eisenberg,et al. Molecular genomic profiling of adrenocortical cancers in clinical practice. , 2020, Surgery.
[10] M. Papotti,et al. The IGF2 methylation score for adrenocortical cancer: an ENSAT validation study. , 2020, Endocrine-related cancer.
[11] E. Kebebew,et al. Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy. , 2020, Surgery.
[12] S. Pakbaz,et al. A Diagnostic Approach to Adrenocortical Tumors. , 2019, Surgical pathology clinics.
[13] P. Igaz,et al. Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy. , 2019, Journal of biotechnology.
[14] P. Igaz. Circulating microRNAs in adrenal tumors , 2019, Current opinion in endocrinology, diabetes, and obesity.
[15] T. Koehler,et al. Adrenocortical oncocytic neoplasm: A systematic review☆ , 2018, Surgery.
[16] Eric Baudin,et al. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. , 2018, European journal of endocrinology.
[17] Chin-Lee Wu,et al. Co-expression Network Analysis of Biomarkers for Adrenocortical Carcinoma , 2018, Front. Genet..
[18] J. Bertherat,et al. MiR‐483‐5p and miR‐139‐5p promote aggressiveness by targeting N‐myc downstream‐regulated gene family members in adrenocortical cancer , 2018, International journal of cancer.
[19] B. Amgai,et al. The Characteristics and Trends in Adrenocortical Carcinoma: A United States Population Based Study , 2018, Journal of clinical medicine research.
[20] E. Baudin,et al. Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation , 2018, Modern Pathology.
[21] A. Tabarin,et al. Diagnostic accuracy of computed tomography to identify adenomas among adrenal incidentalomas in an endocrinological population. , 2018, European journal of endocrinology.
[22] M. Mannelli,et al. Adrenocortical carcinoma: the dawn of a new era of genomic and molecular biology analysis , 2018, Journal of Endocrinological Investigation.
[23] S. Asa,et al. Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma , 2018, The American journal of surgical pathology.
[24] J. Bertherat,et al. Genetics of tumors of the adrenal cortex. , 2017, Endocrine-related cancer.
[25] M. Sibony,et al. Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma. , 2017, Endocrine-related cancer.
[26] W. Dinjens,et al. Identification of Mutations in Cell-Free Circulating Tumor DNA in Adrenocortical Carcinoma: A Case Series. , 2017, The Journal of clinical endocrinology and metabolism.
[27] S. Challa,et al. Diagnosis of Adrenocortical Tumors by Reticulin Algorithm , 2017, Indian journal of endocrinology and metabolism.
[28] P. Igaz,et al. Evaluation and diagnostic potential of circulating extracellular vesicle-associated microRNAs in adrenocortical tumors , 2017, Scientific Reports.
[29] S. Gelmini,et al. New insights in the clinical and translational relevance of miR483-5p in adrenocortical cancer , 2017, Oncotarget.
[30] Michael R. Speicher,et al. Emerging concepts in liquid biopsies , 2017, BMC Medicine.
[31] K. Jażdżewski,et al. Next-generation sequencing reveals microRNA markers of adrenocortical tumors malignancy , 2017, Oncotarget.
[32] M. Papotti,et al. Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma. , 2017, Human pathology.
[33] S. Kopetz,et al. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] M. Papotti,et al. Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis. , 2016, Human pathology.
[35] W. Young,et al. Procedural and clinical outcomes of percutaneous adrenal biopsy in a high‐risk population for adrenal malignancy , 2016, Clinical endocrinology.
[36] B. Leggett,et al. RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis , 2016, Oncotarget.
[37] P. V. van Koetsveld,et al. Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas. , 2016, Endocrine-related cancer.
[38] J. Deeks,et al. MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis , 2016, European journal of endocrinology.
[39] Fares Alahdab,et al. DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis. , 2016, European journal of endocrinology.
[40] A. Tabarin,et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. , 2016, European journal of endocrinology.
[41] Qi Zheng,et al. ZNRF3 is downregulated in papillary thyroid carcinoma and suppresses the proliferation and invasion of papillary thyroid cancer cells , 2016, Tumor Biology.
[42] E. Bessonova,et al. Different Types of Urinary Steroid Profiling Obtained by High-Performance Liquid Chromatography and Gas Chromatography-Mass Spectrometry in Patients with Adrenocortical Carcinoma , 2016, Hormones and Cancer.
[43] Benjamin J Raphael,et al. Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. , 2016, Cancer cell.
[44] Klaus Pantel,et al. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. , 2016, Cancer discovery.
[45] Andrew P Stubbs,et al. An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma , 2016, The American journal of surgical pathology.
[46] W. Young,et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.
[47] Melissa J. Fullwood,et al. Roles, Functions, and Mechanisms of Long Non-coding RNAs in Cancer , 2016, Genom. Proteom. Bioinform..
[48] E. Caoili,et al. 5th International ACC Symposium: Imaging for Diagnosis and Surveillance of Adrenal Tumors—New Advances and Reviews of Old Concepts , 2016, Hormones and Cancer.
[49] G. Scagliotti,et al. Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases. , 2015, Human pathology.
[50] R. Verhaak,et al. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. , 2015, Cancer research.
[51] E. Caoili,et al. Radiographic Characteristics of Adrenal Masses Preceding the Diagnosis of Adrenocortical Cancer , 2015, Hormones and Cancer.
[52] I. Kema,et al. Diagnostic Value of Urinary Steroid Profiling in the Evaluation of Adrenal Tumors , 2015, Hormones and Cancer.
[53] S. Chowdhury,et al. Histopathological study of adrenocortical masses with special references to Weiss score, Ki-67 index and p53 status. , 2015, Indian journal of pathology & microbiology.
[54] R. Kanthan,et al. Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature , 2015, World Journal of Surgical Oncology.
[55] C. Haglund,et al. Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas. , 2015, Human pathology.
[56] Annabelle L. Fonseca,et al. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. , 2015, The Journal of clinical endocrinology and metabolism.
[57] Claudia Eichler-Jonsson,et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] P. Igaz,et al. MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy , 2015, Cellular and Molecular Life Sciences.
[59] M. Papotti,et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. , 2015, The Journal of clinical endocrinology and metabolism.
[60] Andrew P Stubbs,et al. Automated Selection of Hotspots (ASH): enhanced automated segmentation and adaptive step finding for Ki67 hotspot detection in adrenal cortical cancer , 2014, Diagnostic Pathology.
[61] M. Al-Haddad,et al. Role of endoscopic ultrasound fine-needle aspiration evaluating adrenal gland enlargement or mass. , 2014, World journal of nephrology.
[62] P. Stephens,et al. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies , 2014, Journal of Clinical Pathology.
[63] H. Macapinlac,et al. Impact of 18F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[64] Eric Baudin,et al. Integrated genomic characterization of adrenocortical carcinoma , 2014, Nature Genetics.
[65] P. Igaz,et al. Analysis of circulating microRNAs in adrenocortical tumors , 2014, Laboratory Investigation.
[66] J. Bertherat,et al. Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas. , 2014, European journal of endocrinology.
[67] T. Giordano,et al. CT imaging characteristics of oncocytic adrenal neoplasms (OANs): comparison with adrenocortical carcinomas , 2014, Abdominal Imaging.
[68] M. Papotti,et al. Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma , 2014, Modern Pathology.
[69] T. Fojo,et al. MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors. , 2013, Surgery.
[70] Dachun Zhao,et al. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers , 2013, Histopathology.
[71] M. Fassnacht,et al. Update in adrenocortical carcinoma. , 2013, The Journal of clinical endocrinology and metabolism.
[72] A. Rosenwald,et al. Single Nucleotide Polymorphism Array Profiling of Adrenocortical Tumors - Evidence for an Adenoma Carcinoma Sequence? , 2013, PloS one.
[73] M. Papotti,et al. The Reticulin Algorithm for Adrenocortical Tumor Diagnosis: A Multicentric Validation Study on 245 Unpublished Cases , 2013, The American journal of surgical pathology.
[74] J. Bertherat,et al. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. , 2013, Endocrine-related cancer.
[75] M. Paglierani,et al. Detection of circulating tumor cells in patients with adrenocortical carcinoma: a monocentric preliminary study. , 2013, The Journal of clinical endocrinology and metabolism.
[76] J. Dieleman,et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. , 2013, European journal of cancer.
[77] M. Malumbres,et al. miRNAs and cancer: an epigenetics view. , 2013, Molecular aspects of medicine.
[78] A. Buck,et al. [¹²³I]Iodometomidate imaging in adrenocortical carcinoma. , 2013, The Journal of clinical endocrinology and metabolism.
[79] E. Baudin,et al. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. , 2013, The Journal of clinical endocrinology and metabolism.
[80] J. Dieleman,et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993 , 2013 .
[81] A. Buck,et al. [123I]Iodometomidate imaging in adrenocortical carcinoma , 2013 .
[82] A. Buck,et al. Functional characterization of adrenal lesions using [123I]IMTO-SPECT/CT. , 2013, The Journal of clinical endocrinology and metabolism.
[83] I. Yasuda,et al. Preoperative routine evaluation of bilateral adrenal glands by endoscopic ultrasound and fine-needle aspiration in patients with potentially resectable lung cancer , 2013, Endoscopy.
[84] Annabelle L. Fonseca,et al. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors , 2012, Genes, chromosomes & cancer.
[85] V. Viallon,et al. Adrenocortical Tumors: Improving the Practice of the Weiss System Through Virtual Microscopy A National Program of the French Network INCa-COMETE , 2012, The American journal of surgical pathology.
[86] P. Meltzer,et al. DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. , 2012, The Journal of clinical endocrinology and metabolism.
[87] E. Lalli,et al. Dysregulation of microRNAs in adrenocortical tumors , 2012, Molecular and Cellular Endocrinology.
[88] J. Bertherat,et al. Clinical and pathophysiological implications of chromosomal alterations in adrenocortical tumors: an integrated genomic approach. , 2012, The Journal of clinical endocrinology and metabolism.
[89] M. Papotti,et al. Oncocytic Adrenocortical Tumors: Diagnostic Algorithm and Mitochondrial DNA Profile in 27 Cases , 2011, The American journal of surgical pathology.
[90] S. Hahner,et al. Metomidate-Based Imaging of Adrenal Masses , 2011, Hormones & cancer.
[91] Michael Biehl,et al. Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors , 2011, The Journal of clinical endocrinology and metabolism.
[92] C. Larsson,et al. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma , 2011, Endocrine-related cancer.
[93] T. Fojo,et al. MicroRNA profiling of adrenocortical tumors reveals miR‐483 as a marker of malignancy , 2011, Cancer.
[94] K. Schmid,et al. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours , 2011, Journal of Clinical Pathology.
[95] M. Platten,et al. Oncocytic adrenocortical neoplasms--a clinicopathologic study of 13 new cases emphasizing the importance of their recognition. , 2011, Human pathology.
[96] J. Bertherat,et al. Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. , 2011, Endocrine-related cancer.
[97] M. Kalra,et al. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. , 2011, Radiology.
[98] Martin Fassnacht,et al. Adrenocortical carcinoma: a clinician's update , 2011, Nature Reviews Endocrinology.
[99] F. Tissier. Classification of adrenal cortical tumors: what limits for the pathological approach? , 2010, Best practice & research. Clinical endocrinology & metabolism.
[100] F. Beuschlein,et al. Deficits in the management of patients with adrenocortical carcinoma in Germany. , 2010, Deutsches Arzteblatt international.
[101] L. Nieman,et al. Approach to the patient with an adrenal incidentaloma. , 2010, The Journal of clinical endocrinology and metabolism.
[102] F. Beuschlein,et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. , 2010, The Journal of clinical endocrinology and metabolism.
[103] M. Papotti,et al. Adrenocortical Tumors With Myxoid Features: A Distinct Morphologic and Phenotypical Variant Exhibiting Malignant Behavior , 2010, The American journal of surgical pathology.
[104] P. Igaz,et al. Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed , 2010, Oncogene.
[105] C. Leux,et al. 18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[106] J. Bertherat,et al. The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses , 2010, Trends in Endocrinology & Metabolism.
[107] F. Montorsi,et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. , 2010, European journal of cancer.
[108] Jeffrey E. Lee,et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma , 2009, Cancer.
[109] Anthony J Gill,et al. miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer , 2009, Clinical Cancer Research.
[110] M. Papotti,et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification , 2009, Histopathology.
[111] P. Igaz,et al. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. , 2009, Endocrine-related cancer.
[112] C. Larsson,et al. Transcriptional profiling enables molecular classification of adrenocortical tumours. , 2009, European journal of endocrinology.
[113] A. Gill,et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. , 2009, Endocrine-related cancer.
[114] L. Weiss,et al. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. , 2009, Human pathology.
[115] Martin Fassnacht,et al. Clinical management of adrenocortical carcinoma. , 2009, Best practice & research. Clinical endocrinology & metabolism.
[116] Bertrand Dousset,et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] Paul G. Gauger,et al. Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling , 2009, Clinical Cancer Research.
[118] F. Beuschlein,et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma , 2009, Cancer.
[119] A. Mcnicol,et al. A Diagnostic Approach to Adrenal Cortical Lesions , 2008, Endocrine pathology.
[120] R. Yeh,et al. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. , 2008, Archives of surgery.
[121] R. Reznek,et al. The optimal imaging of adrenal tumours: a comparison of different methods. , 2007, Endocrine-related cancer.
[122] L. Bastian,et al. Cortisol as a possible marker of metastatic adrenocortical carcinoma: a case report with 3-year follow-up. , 2007, Anticancer research.
[123] M. Yun,et al. Analysis of adrenal masses by 18F‐FDG positron emission tomography scanning , 2007, International journal of clinical practice.
[124] C. Elie,et al. Somatic TP53 Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17p13 Loss of Heterozygosity , 2007, Clinical Cancer Research.
[125] V. Rousson,et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours , 2006, Histopathology.
[126] P. Choyke. ACR Appropriateness Criteria on incidentally discovered adrenal mass. , 2006, Journal of the American College of Radiology : JACR.
[127] M. Bergström,et al. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. , 2006, The Journal of clinical endocrinology and metabolism.
[128] G. Scagliotti,et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series , 2006, Journal of endocrinological investigation.
[129] D. Bartsch,et al. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. , 2006, European journal of endocrinology.
[130] Q. Duh,et al. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? , 2006, Journal of the American College of Surgeons.
[131] Joakim Lundeberg,et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. , 2005, Surgery.
[132] J. Bertherat,et al. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. , 2005, European journal of endocrinology.
[133] J. Bertherat,et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. , 2005, Cancer research.
[134] F. Berger,et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. , 2005, The Journal of clinical endocrinology and metabolism.
[135] Allan Siperstein,et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. , 2005, The Journal of clinical endocrinology and metabolism.
[136] M. Bisceglia,et al. Adrenocortical Oncocytic Tumors: Report of 10 Cases and Review of the Literature , 2004, International journal of surgical pathology.
[137] W. Wadsak,et al. Positron emission tomography imaging of adrenal masses: 18F-fluorodeoxyglucose and the 11β-hydroxylase tracer 11C-metomidate , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[138] K. Någren,et al. Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[139] C. Cordon-Cardo,et al. Adrenocortical Adenoma and Carcinoma: Histopathological and Molecular Comparative Analysis , 2003, Modern Pathology.
[140] L. Thompson,et al. Adrenal Cortical Neoplasms in the Pediatric Population: A Clinicopathologic and Immunophenotypic Analysis of 83 Patients , 2003, The American journal of surgical pathology.
[141] Paul G Gauger,et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. , 2003, The American journal of pathology.
[142] P. Devos,et al. Weiss System Revisited: A Clinicopathologic and Immunohistochemical Study of 49 Adrenocortical Tumors , 2002, The American journal of surgical pathology.
[143] P. Heikkilä,et al. Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. , 2002, The Journal of clinical endocrinology and metabolism.
[144] E. Baudin,et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. , 2001, Cancer research.
[145] I. Francis,et al. Delayed enhanced CT of lipid-poor adrenal adenomas. , 2000, AJR. American journal of roentgenology.
[146] C. Gicquel,et al. Fibroblast Growth Factor-2 Inhibits the Maturation of Pro-Insulin-Like Growth Factor-II (Pro-IGF-II) and the Expression of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in the Human Adrenocortical Tumor Cell Line NCI-H295R. , 2000, Endocrinology.
[147] J. Rastad,et al. PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[148] G. Arnaldi,et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. , 2000, The Journal of clinical endocrinology and metabolism.
[149] K. Salmenkivi,et al. P53 and Ki67 in Adrenocortical Tumors , 2000, Endocrine research.
[150] E. Speel,et al. Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. , 1999, The American journal of pathology.
[151] C. Larsson,et al. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. , 1999, The Journal of clinical endocrinology and metabolism.
[152] D. Szolar,et al. Adrenal adenomas and nonadenomas: assessment of washout at delayed contrast-enhanced CT. , 1998, Radiology.
[153] C. Gicquel,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Increased Levels of Insulin-Like Growth Factor II (IGF-II) and IGF-Binding Protein-2 Are Associated with Malignancy in Sporadic Adrenocortical Tum , 2022 .
[154] L. Quint,et al. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. , 1998, AJR. American journal of roentgenology.
[155] C. Larsson,et al. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. , 1996, Cancer research.
[156] G. Chrousos,et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. , 1994, The Journal of clinical endocrinology and metabolism.
[157] P Blondeau,et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. , 1990, The New England journal of medicine.
[158] D. Ross,et al. Incidentally discovered adrenal masses. , 1989, American journal of surgery.
[159] L. Medeiros,et al. Pathologic Features of Prognostic Significance in Adrenocortical Carcinoma , 1989, The American journal of surgical pathology.
[160] W. Sippell,et al. Evidence of 11 beta‐hydroxylase deficiency in childhood adrenocortical tumors. The plasma corticosterone/11‐deoxycorticosterone ratio as a possible marker for malignancy , 1987, Cancer.
[161] H. Slooten,et al. Morphologic characteristics of benign and malignant adrenocortical tumors , 1985, Cancer.
[162] K Kinoshita,et al. Measurement of urinary steroid profile in patients with adrenal tumor as a screening method for carcinoma. , 1985, Endocrinologia japonica.
[163] L. Weiss. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors , 1984, The American journal of surgical pathology.
[164] D. Page,et al. Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data. , 1979, American journal of clinical pathology.
[165] S. Jolly,et al. Adrenocortical Carcinoma , 2010, Cancers.
[166] J. Bertherat,et al. Identification of a CpG island methylator phenotype in adrenocortical carcinomas. , 2013, The Journal of clinical endocrinology and metabolism.
[167] M. Esteller,et al. DNA methylation and cancer. , 2010, Advances in genetics.
[168] W. Young. Clinical practice. The incidentally discovered adrenal mass. , 2007, The New England journal of medicine.
[169] W. Wadsak,et al. Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate. , 2004, European journal of nuclear medicine and molecular imaging.
[170] P. De Giuli,et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. , 2001, Urology.
[171] E. Małunowicz,et al. Heterogeneity of urinary steroid profiles in children with adrenocortical tumors. , 1995, Hormone research.